APC to commercialize new bacterial strain for metabolic and mental health
date:Dec 21, 2020
A new bacterial strain could address the obesity crisis thanks to its impact on metabolism and stress. The APC Microbiome Ireland SFI Research Centre, which identified and patented Bifidobacterium longum APC1472, is now talking to interested parties about the commercialization of the strain.

The findings highlight the promising potential of B. longum APC1472 to be developed as a valuable probiotic supplement to reduce blood glucose. This is important in the development of conditions such as Typ
1/9 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/24 02:27